European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Description du projet

Réseau européen de formation à la recherche translationnelle sur le glioblastome

Le glioblastome (GBM) est un cancer du cerveau très agressif et mortel: 85 % des patients succombent dans les deux ans. Il n’existe actuellement pas de traitement efficace pour le GBM et il est urgent de mettre au point de nouvelles options thérapeutiques. Le projet GLIOTRAIN, financé par le programme Actions Marie Skłodowska-Curie, se concentrera sur le développement d’un réseau européen de formation à la recherche composé de 14 organisations issues de huit pays, afin de former 15 jeunes chercheurs créatifs. L’objectif de GLIOTRAIN est de découvrir de nouvelles stratégies thérapeutiques de traitement du GBM, en utilisant le séquençage de nouvelle génération, la médecine systémique et la multi-omique intégrative pour comprendre les mécanismes de résistance à la maladie. Le réseau du projet préparera une nouvelle génération de scientifiques à la recherche translationnelle et aux soins cliniques du GBM.

Objectif

Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

Coordinateur

ROYAL COLLEGE OF SURGEONS IN IRELAND
Contribution nette de l'UE
€ 1 062 698,40
Adresse
ST STEPHEN'S GREEN 123
2 Dublin
Irlande

Voir sur la carte

Région
Ireland Northern and Western Border
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 1 062 698,40

Participants (8)

Partenaires (14)